Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012687 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
A NA study of Essential Hypertension, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01012687 is a NA study of Essential Hypertension that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants, below the 798-participant average among 8 other Essential Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01012687, a NA study of Essential Hypertension, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
Conditions Studied
Interventions
- DRUG perindopril erbumine
Study Locations (1)
Texas
- Novum Pharmaceutical Research Services - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012687
The ClinicalTrials.gov registry entry for NCT01012687 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 798-participant average among 8 other Essential Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 1 intervention - of which perindopril erbumine is the first listed.
NCT01012687 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01012687 about?
NCT01012687 is a clinical study titled "Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
What is the current status of trial NCT01012687?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2007-04. Estimated completion is 2007-05.
What conditions does trial NCT01012687 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT01012687?
The interventions under investigation include: perindopril erbumine (DRUG).
Who is sponsoring clinical trial NCT01012687?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01012687 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.